Natural history of Ollier disease and Maffucci syndrome: Patient survey and review of clinical literature. Issue 5 (7th March 2020)

• Record Type: Journal Article
• Authors: El Abiad, Jad M.; Robbins, Sarah M.; Cohen, Bernard; Levin, Adam S.; Valle, David L.; Morris, Carol D.; de Macena Sobreira, Nara L.
• Is Part Of: American journal of medical genetics. Volume 182:Issue 5(2020)
• Page Start: 1093
• Page End: 1103
• Publication Date: 2020-03-07
• Subjects: enchondroma -- Maffucci syndrome -- malignancy -- natural history -- Ollier disease -- vascular anomaly; Medical genetics -- Periodicals; 616.14205
• DOI: 10.1002/ajmg.a.61530
• Languages: English
• ISSNs: 1552-4825

Abstract

Abstract: Ollier disease (OD) and Maffucci syndrome (MS) are characterized by multiple enchondromas. Patients with MS also have benign vascular overgrowths that become malignant in 8.5% of cases. OD is characterized by multiple enchondromas, typically unilateral in distribution with a predilection for the appendicular skeleton. MS is characterized by multiple enchondromas bilaterally distributed in most of the cases. Both disorders feature multiple swellings on the extremity, deformity around the joints, limitations in joint mobility, scoliosis, bone shortening, leg‐length discrepancy, gait disturbances, pain, loss of function, and pathological fractures. About 50% of patients with OD or MS develop a malignancy, such as chondrosarcoma, glioma, and ovarian juvenile granulosa cell tumor. To better understand the natural history of OD and MS, we reviewed 287 papers describing patients with OD and MS. We also created a survey that was distributed directly to 162 patients through Facebook. Here, we compare the review of the cases described in the literature to the survey's responses. The review of the literature showed that: the patients with OD are diagnosed at a younger age; the prevalence of chondrosarcomas among patients with OD or MS was ~30%; in four patients, vascular anomalies were identified in internal organs only; and, the prevalence of cancer among patients with OD or MS was ~50%. With these data, health care providers will better understand the natural history, severity, and prognosis of these diseases and the prevalence of malignancies in these patients. Here, we recommend new guidelines for the care of patients with OD and MS.